Opportunity ID: 336578

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-EY-21-002
Funding Opportunity Title: Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.867 — Vision Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Nov 17, 2021
Last Updated Date: Nov 17, 2021
Original Closing Date for Applications: Feb 17, 2022
Current Closing Date for Applications: Feb 17, 2022
Archive Date: Mar 25, 2022
Estimated Total Program Funding:
Award Ceiling: $250,000
Award Floor:

Eligibility

Eligible Applicants: County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal governments (Federally recognized)
City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Public housing authorities/Indian housing authorities
Special district governments
Private institutions of higher education
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Small businesses
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2). The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-EY-21-002.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Version History

Version Modification Description Updated Date

Folder 336578 Full Announcement-RFA-EY-21-002 -> RFA-EY-21-002-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email: OERWebmaster03@od.nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-G Use for due dates on or after January 25, 2022 PKG00270452 Jan 14, 2022 Feb 17, 2022 View
FORMS-F Use for due dates on or before January 24, 2022 PKG00270378 Jan 14, 2022 Jan 24, 2022 View

Package 1

Mandatory forms

336578 RR_SF424_5_0-5.0.pdf

336578 PHS398_CoverPageSupplement_5_0-5.0.pdf

336578 RR_OtherProjectInfo_1_4-1.4.pdf

336578 PerformanceSite_4_0-4.0.pdf

336578 RR_KeyPersonExpanded_4_0-4.0.pdf

336578 PHS398_ResearchPlan_4_0-4.0.pdf

336578 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

336578 RR_Budget_3_0-3.0.pdf

336578 RR_SubawardBudget30_3_0-3.0.pdf

336578 PHS398_ModularBudget_1_2-1.2.pdf

336578 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

336578 RR_SF424_2_0-2.0.pdf

336578 PHS398_CoverPageSupplement_5_0-5.0.pdf

336578 RR_OtherProjectInfo_1_4-1.4.pdf

336578 PerformanceSite_2_0-2.0.pdf

336578 RR_KeyPersonExpanded_2_0-2.0.pdf

336578 PHS398_ResearchPlan_4_0-4.0.pdf

336578 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

336578 RR_Budget_1_4-1.4.pdf

336578 RR_SubawardBudget30_1_4-1.4.pdf

336578 PHS398_ModularBudget_1_2-1.2.pdf

336578 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-12T06:04:45-05:00

Share This Post, Choose Your Platform!

About the Author: